Somatostatin receptor imaging (SRI) with [111 In-DTPA 0] octreotide has proven its role in
the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs) …

Somatostatin receptor imaging (SRI) with [111In-DTPA0] octreotide has proven its role in the
diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). Newer …

This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …

The purpose of these guidelines is to assist physicians caring for patients with
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …

Purpose Despite the fact that most gastroenteropancreatic neuroendocrine tumors
(GEPNETs) are slowgrowing, median overall survival (OS) in patients with liver metastases …

Abstract Purpose Radionuclide therapy with 177Lu-DOTATATE is well established for
patients with advanced somatostatin receptor–positive neuroendocrine tumors with a …

Purpose There are few treatment options for patients with metastasized or inoperable
endocrine gastroenteropancreatic (GEP) tumors. Chemotherapy can be effective, but the …

Purpose Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with 90
Y-DOTATOC and 177 Lu-DOTATATE is promising. The kidney is the critical organ and …

Abstract Treatment with radiolabelled somatostatin analogues is a promising new tool in the
management of patients with inoperable or metastasized neuroendocrine tumours …

JK Ramage*, AHG Davies*, J ArdillÀ, N BaxÀ, M CaplinÀ, A GrossmanÀ, R HawkinsÀ, AM
McNicolÀ, N ReedÀ, R Sutton, R ThakkerÀ, S Aylwin, D Breen, K Britton, K Buchanan, P …